ReviewThe EPMA journal2016
The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue.
Review in The EPMA journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03759249 (Control Fatigue), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Control Fatigue: Sleep Medical Treatment as a Novel Therapeutic Approach to an Unmet Medical Need in Multiple Sclerosis
Who cites it
26 citing papers in PubMed, 72 citations in OpenAlex.
- Efficacy of an Internet-Based Program to Promote Physical Activity and Exercise after Inpatient Rehabilitation in Persons with Multiple Sclerosis: A Randomized, Single-Blind, Controlled Study.International journal of environmental research and public health · 2020Trial
- Subjective mental fatigue mediates the relationship between information processing speed and verbal memory deficits in multiple sclerosis.Scientific reports · 2026Article
- Behavioral disorders in multiple sclerosis: a comprehensive review.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Sleep Disorders and Fatigue among Patients with MS: The Role of Depression, Stress, and Anxiety.Neurology research international · 2024Article
- Role of selective attention in fatigue in neurological disorders.European journal of neurology · 2023Review
- Measuring objective fatigability and autonomic dysfunction in clinical populations: How and why?Frontiers in sports and active living · 2023Review
- Enhancing Mood, Cognition, and Quality of Life in Pediatric Multiple Sclerosis.Paediatric drugs · 2021Review
- What's in a name? That which we callMultiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Article
- Longitudinal analysis of primary and secondary factors related to fatigue in multiple sclerosis.Acta neurologica Belgica · 2021Observational
- Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients.Scientific reports · 2020Article
- Surveying sleep quality and fatigue in multiple sclerosis patients at a multiple sclerosis center in Kermanshah, Iran, in 2017.Neurobiology of sleep and circadian rhythms · 2020Article
- Vitamin D deficiency and its association with fatigue and quality of life in multiple sclerosis patients.The EPMA journal · 2020Article
- Association Between Fatigue and Motor Exertion in Patients With Multiple Sclerosis-a Prospective Study.Frontiers in neurology · 2020Article
- Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.Frontiers in neurology · 2020Review
- Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials.The EPMA journal · 2019Review
- Flammer syndrome in multiple sclerosis: diagnostics, prediction, and personalization of treatments.The EPMA journal · 2019Article
- Subjective and physiological stress measurement in a multiple sclerosis sample and the relation with executive functions performance.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Nocturia in Patients With Multiple Sclerosis.Reviews in urology · 2019Article
- Multiple sclerosis.Nature reviews. Disease primers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 80% of multiple sclerosis (MS) patients suffer from fatigue. Despite this, there are few therapeutic options and evidence-based pharmacological treatments are lacking. The associated societal burden is substantial (MS fatigue is a major reason for part-time employment or early retirement), and at least one out of four MS patients view fatigue as the most burdensome symptom of their disease. The mechanisms underlying MS-related fatigue are poorly understood, and objective criteria for distinguishing and evaluating levels of fatigue and tiredness have not yet been developed. A further complication is that both symptoms may also be unspecific indicators of many other diseases (including depression, sleep disorders, anemia, renal failure, liver diseases, chronic obstructive pulmonary disease, drug side effects, recent MS relapses, infections, nocturia, cancer, thyroid hypofunction, lack of physical exercise). This paper reviews current treatment options of MS-related fatigue in order to establish an individualized therapeutic strategy that factors in existing comorbid disorders. To ensure that such a strategy can also be easily and widely implemented, a comprehensive approach is needed, which ideally takes into account all other possible causes and which is moreover cost efficient. Using a diagnostic interview, depressive disorders, sleep disorders and side effects of the medication should be identified and addressed. All MS patients suffering from fatigue should fill out the Modified Fatigue Impact Scale, Epworth Sleepiness Scale, the Beck Depression Inventory (or a similar depression scale), and the Pittsburgh Sleep Quality Index (or the Insomnia Severity Index). In some patients, polygraphic or polysomnographic investigations should be performed. The treatment of underlying sleep disorders, drug therapy with alfacalcidol or fampridine, exercise therapy, and cognitive behavioral therapy-based interventions may be effective against MS-related fatigue. The objectives of this article are to identify the reasons for fatigue in patients suffering from multiple sclerosis and to introduce individually tailored treatment approaches. Moreover, this paper focuses on current knowledge about MS-related fatigue in relation to brain atrophy and lesions, cognition, disease course, and other findings in an attempt to identify future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.